Duvelisib Had Consistent Response Rates in R/R Peripheral T-Cell Lymphoma
Response appears to be consistent across histological subtypes.
Response appears to be consistent across histological subtypes.
Response depth appeared to be predictive of PFS in WM patients treated with ibrutinib.
Using the FACT-G questionnaire, researchers measured the quality of life for survivors of aggressive lymphomas at diagnosis and at various time points up to 9 years postdiagnosis.
A St Jude Children’s Research Hospital team investigated potential causes of neurocognitive impairments in survivors of childhood Hodgkin lymphoma survivors.
Nearly half of all relapses occurred within the first month of CAR-T infusion.
Peripheral T-cell lymphoma is characterized by extensive epigenetic dysregulation.
Researchers examined data from patients who were treated for Hodgkin lymphoma between 2009 and 2013 who had received radiation therapy as part of their treatment.
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
Study results demonstrate influence of the ASH Choosing Wisely campaign regarding surveillance imaging rates in patients with DLBCL.
A retrospective analysis highlights the reasons for discontinuation of ibrutinib among patients with mantle cell lymphoma.